APOE and Alzheimer disease: Further cross‐validated confusion matrices showed that among APOE ε4 carriers, 89.23% of AD patients were correctly identified by Model 3, 10.77% were incorrectly classified as NC individuals, and 15.79% of the NC group was misclassified.